HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IQV
IQVIA Holdings Inc.
IQV's fundamentals are mixed: it turned 12% of its revenue into free cash flow, while its operating margin held steady at 13%. At 33x earnings, it's trading in line with its usual 36x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IQV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Weak |
IQV's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IQV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $271 | — |
| Cheap | 27x | $218 | -19% |
| Current | 33x | $271 | — |
| Fair | 36x | $292 | +7.6% |
| Expensive | 124x | $1,021 | +277% |
Historical ranges are pointers, not guarantees.
IQV's PE is in its fair range at 33x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IQV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
IQV has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IQV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.78 | +68% |
| Q3 2026 | $8.21 | +13% |
| Q2 2026 | $8.04 | +17% |
| Q1 2026 | $8.05 | +9.8% |
| Q4 2025 | $7.84 | +4.7% |
| Q3 2025 | $7.28 | -4.5% |
| Q2 2025 | $6.90 | -10% |
| Q1 2025 | $7.33 | +0.1% |
| Q4 2024 | $7.49 | +2.7% |
IQV has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IQV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IQV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | +8% |
| Q2 2026 | $4.4B | +8.7% |
| Q1 2026 | $4.2B | +8.4% |
| Q4 2025 | $4.4B | +10% |
| Q3 2025 | $4.1B | +5.2% |
| Q2 2025 | $4B | +5.3% |
| Q1 2025 | $3.8B | +2.5% |
| Q4 2024 | $4B | +2.3% |
IQV's revenue has grown year over year every quarter since late 2020: $4.4B last quarter, up 8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.6 points |
| Q2 2026 | 12% | -1 points |
| Q1 2026 | 12% | -0.6 points |
| Q4 2025 | 14% | -1.5 points |
| Q3 2025 | 13% | -0.6 points |
| Q2 2025 | 13% | -1 points |
| Q1 2025 | 13% | -0.6 points |
| Q4 2024 | 16% | +2.9 points |
IQV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IQV on cash flow, with more consistent year-over-year improvement.
IQV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $667M | -14% |
| Q2 2026 | $360M | +23% |
| Q1 2026 | $491M | +15% |
| Q4 2025 | $561M | -22% |
| Q3 2025 | $772M | +35% |
| Q2 2025 | $292M | -34% |
| Q1 2025 | $426M | +13% |
| Q4 2024 | $721M | +27% |
IQV's free cash flow has been positive every quarter for seven years: $2.1B over the past year, down 6% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IQV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IQV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -300K shares |
| 1 year | -2.7% | -4.7M shares |
| 3 years | -10% | -18.5M shares |
| 5 years | -14% | -28.3M shares |
| Available history | -16% | -32.6M shares |
IQV has 167M diluted shares, down 2.7% from a year ago, with $1.2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $398M |
| Q1 2026 | $552M |
| Q4 2025 | $212M |
| Q3 2025 | — |
| Q2 2025 | $657M |
| Q1 2025 | $375M |
| Q4 2024 | $1.2B |
IQV spent $1.2B buying back its own shares over the past year, down 47% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IQV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.1x | High |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 3.7x | Elevated |
IQV's net debt is about 4.0 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IQV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.2 | Neutral |
| Stochastic | 76.5 | Neutral |
IQV's weekly RSI is 65 (neutral) and its Stochastic is 76 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IQV PE vs Healthcare Sector
| Metric | IQV | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 28% above |
| PE % | 38 | 29 | 9 pts above |
IQV is trading at 33x earnings, a 28% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IQV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $268.1 | 1.1% above |
| 20 week MA | $250.1 | 8.4% above |
| 50 week MA | $213.9 | 27% above |
| 100 week MA | $198.5 | 37% above |
| 200 week MA | $208.6 | 30% above |
IQV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IQV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $154.4 | $175.9 | +14% |
| 2021 | $175.9 | $278.0 | +58% |
| 2022 | $278.0 | $203.8 | -27% |
| 2023 | $203.8 | $231.4 | +14% |
| 2024 | $231.4 | $199.4 | -14% |
| 2025 | $199.4 | $226.9 | +14% |
| 2026 YTD | $226.9 | $271.1 | +19% |
IQV has the edge over HIMS on returns for 2026, with the stronger performance.